Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation
Central role of LDL in atherogenesis Among the many contributing factors, elevated cholesterol levels play a dominant role in both the initiation and progression of atherosclerosis, as well as in the clinical consequences such as myocardial infarction, stroke, peripheral vascular disease, and heart...
Gespeichert in:
Veröffentlicht in: | Diabetes care 2008-04, Vol.31 (4), p.811-822 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 822 |
---|---|
container_issue | 4 |
container_start_page | 811 |
container_title | Diabetes care |
container_volume | 31 |
creator | Brunzell, John D Davidson, Michael Furberg, Curt D Goldberg, Ronald B Howard, Barbara V Stein, James H Witztum, Joseph L |
description | Central role of LDL in atherogenesis Among the many contributing factors, elevated cholesterol levels play a dominant role in both the initiation and progression of atherosclerosis, as well as in the clinical consequences such as myocardial infarction, stroke, peripheral vascular disease, and heart failure. In terms of dyslipoproteinemia, we recommend the following: * Statin therapy for the majority of dyslipoproteinemic adult patients with CMR * For patients with CMR on statin therapy, guiding therapy with measurements of apoB and treatment to apoB goals in addition to LDL cholesterol and non-HDL cholesterol assessments * Treatment goals, summarized in Table 1, that address the high lifetime risk of patients with dyslipoproteinemia and CMR. * Clinical trials to determine whether the pharmacologic therapy required to achieve very low levels of atherogenic lipoproteins is safe and cost-effective * A concerted, multifaceted, public health effort, focused on lifestyle modification, to reduce mean population levels of atherogenic lipoproteins to values well below current ones. |
doi_str_mv | 10.2337/dc08-9018 |
format | Article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_70449356</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A177953507</galeid><sourcerecordid>A177953507</sourcerecordid><originalsourceid>FETCH-LOGICAL-f282t-8ca26ca63e19ef44b98e936fd15e0c59838843a835c3c2d5a24cfdc9355e4443</originalsourceid><addsrcrecordid>eNpt0ctu1DAUBuAIgehQWPACYCHBLsXXidPdKFBAGgSCIpbRGec4dUnswXYWfSWeEsMMSKDKC1_0HfvXcVU9ZvSMC9G8HAzVdUuZvlOtWCtUrZTUd6sVZbKtVdvyk-pBSteUUim1vl-dMC0aJQVbVT-2bh_2MWR0nrwHDyPO6DMpu4-QXVkm8tXlK9JBHFyYMcMuTM6QTy59Oydd8Al9WhJJGfKh1MYwk3yFZDNjdAY8eeVghxkT2aQUjCv3Bk_AD_-qLkwTjkiCPT42hfGGXITFD78rHlb3LEwJHx3n0-ry4vVl97befnjzrttsa8s1z7U2wNcG1gJZi1bKXauxFWs7MIXUqFYLraUALZQRhg8KuDR2MKVtCqWU4rR6cbi2dOX7gin3s0sGpwk8hiX1TWliwesCn_0Hr8MSfYnWcy4op5ypguoDGmHC3nkbcgQzoscIU_BoXTnesKZplVC0Kf7sFl_GgLMztxY8OaZYdjMO_T66GeJN_-eLC3h-BJAMTDaCNy79dSWmLGF_JX16cBZCD2Ms5stnTpmgVDear4X4CczVvvk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223020215</pqid></control><display><type>article</type><title>Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Brunzell, John D ; Davidson, Michael ; Furberg, Curt D ; Goldberg, Ronald B ; Howard, Barbara V ; Stein, James H ; Witztum, Joseph L</creator><creatorcontrib>Brunzell, John D ; Davidson, Michael ; Furberg, Curt D ; Goldberg, Ronald B ; Howard, Barbara V ; Stein, James H ; Witztum, Joseph L ; American College of Cardiology Foundation ; American Diabetes Association</creatorcontrib><description>Central role of LDL in atherogenesis Among the many contributing factors, elevated cholesterol levels play a dominant role in both the initiation and progression of atherosclerosis, as well as in the clinical consequences such as myocardial infarction, stroke, peripheral vascular disease, and heart failure. In terms of dyslipoproteinemia, we recommend the following: * Statin therapy for the majority of dyslipoproteinemic adult patients with CMR * For patients with CMR on statin therapy, guiding therapy with measurements of apoB and treatment to apoB goals in addition to LDL cholesterol and non-HDL cholesterol assessments * Treatment goals, summarized in Table 1, that address the high lifetime risk of patients with dyslipoproteinemia and CMR. * Clinical trials to determine whether the pharmacologic therapy required to achieve very low levels of atherogenic lipoproteins is safe and cost-effective * A concerted, multifaceted, public health effort, focused on lifestyle modification, to reduce mean population levels of atherogenic lipoproteins to values well below current ones.</description><identifier>ISSN: 0149-5992</identifier><identifier>EISSN: 1935-5548</identifier><identifier>DOI: 10.2337/dc08-9018</identifier><identifier>PMID: 18375431</identifier><identifier>CODEN: DICAD2</identifier><language>eng</language><publisher>Alexandria, VA: American Diabetes Association</publisher><subject>Aqueous solutions ; Biological and medical sciences ; Blood lipoproteins ; Cardiovascular disease ; Cardiovascular diseases ; Cardiovascular Diseases - blood ; Cardiovascular Diseases - epidemiology ; Cardiovascular Diseases - prevention & control ; Care and treatment ; Cholesterol ; Cholesterol, LDL - blood ; Diabetes ; Diabetes Mellitus, Type 2 - complications ; Diabetes. Impaired glucose tolerance ; Diabetic Angiopathies - blood ; Diabetic Angiopathies - epidemiology ; Diabetic Angiopathies - prevention & control ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Heart failure ; Humans ; Kidney diseases ; Lipoproteins ; Lipoproteins - blood ; Lipoproteins - metabolism ; Medical sciences ; Metabolic diseases ; Miscellaneous ; Mortality ; Other metabolic disorders ; Physiological aspects ; Plasma ; Proteolipids ; Public health ; Public health. Hygiene ; Public health. Hygiene-occupational medicine ; Risk Factors ; Societies, Medical ; Type 2 diabetes ; United States ; Voluntary Health Agencies</subject><ispartof>Diabetes care, 2008-04, Vol.31 (4), p.811-822</ispartof><rights>2008 INIST-CNRS</rights><rights>COPYRIGHT 2008 American Diabetes Association</rights><rights>Copyright American Diabetes Association Apr 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20243025$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18375431$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brunzell, John D</creatorcontrib><creatorcontrib>Davidson, Michael</creatorcontrib><creatorcontrib>Furberg, Curt D</creatorcontrib><creatorcontrib>Goldberg, Ronald B</creatorcontrib><creatorcontrib>Howard, Barbara V</creatorcontrib><creatorcontrib>Stein, James H</creatorcontrib><creatorcontrib>Witztum, Joseph L</creatorcontrib><creatorcontrib>American College of Cardiology Foundation</creatorcontrib><creatorcontrib>American Diabetes Association</creatorcontrib><title>Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation</title><title>Diabetes care</title><addtitle>Diabetes Care</addtitle><description>Central role of LDL in atherogenesis Among the many contributing factors, elevated cholesterol levels play a dominant role in both the initiation and progression of atherosclerosis, as well as in the clinical consequences such as myocardial infarction, stroke, peripheral vascular disease, and heart failure. In terms of dyslipoproteinemia, we recommend the following: * Statin therapy for the majority of dyslipoproteinemic adult patients with CMR * For patients with CMR on statin therapy, guiding therapy with measurements of apoB and treatment to apoB goals in addition to LDL cholesterol and non-HDL cholesterol assessments * Treatment goals, summarized in Table 1, that address the high lifetime risk of patients with dyslipoproteinemia and CMR. * Clinical trials to determine whether the pharmacologic therapy required to achieve very low levels of atherogenic lipoproteins is safe and cost-effective * A concerted, multifaceted, public health effort, focused on lifestyle modification, to reduce mean population levels of atherogenic lipoproteins to values well below current ones.</description><subject>Aqueous solutions</subject><subject>Biological and medical sciences</subject><subject>Blood lipoproteins</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>Cardiovascular Diseases - blood</subject><subject>Cardiovascular Diseases - epidemiology</subject><subject>Cardiovascular Diseases - prevention & control</subject><subject>Care and treatment</subject><subject>Cholesterol</subject><subject>Cholesterol, LDL - blood</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Diabetic Angiopathies - blood</subject><subject>Diabetic Angiopathies - epidemiology</subject><subject>Diabetic Angiopathies - prevention & control</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Heart failure</subject><subject>Humans</subject><subject>Kidney diseases</subject><subject>Lipoproteins</subject><subject>Lipoproteins - blood</subject><subject>Lipoproteins - metabolism</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Miscellaneous</subject><subject>Mortality</subject><subject>Other metabolic disorders</subject><subject>Physiological aspects</subject><subject>Plasma</subject><subject>Proteolipids</subject><subject>Public health</subject><subject>Public health. Hygiene</subject><subject>Public health. Hygiene-occupational medicine</subject><subject>Risk Factors</subject><subject>Societies, Medical</subject><subject>Type 2 diabetes</subject><subject>United States</subject><subject>Voluntary Health Agencies</subject><issn>0149-5992</issn><issn>1935-5548</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpt0ctu1DAUBuAIgehQWPACYCHBLsXXidPdKFBAGgSCIpbRGec4dUnswXYWfSWeEsMMSKDKC1_0HfvXcVU9ZvSMC9G8HAzVdUuZvlOtWCtUrZTUd6sVZbKtVdvyk-pBSteUUim1vl-dMC0aJQVbVT-2bh_2MWR0nrwHDyPO6DMpu4-QXVkm8tXlK9JBHFyYMcMuTM6QTy59Oydd8Al9WhJJGfKh1MYwk3yFZDNjdAY8eeVghxkT2aQUjCv3Bk_AD_-qLkwTjkiCPT42hfGGXITFD78rHlb3LEwJHx3n0-ry4vVl97befnjzrttsa8s1z7U2wNcG1gJZi1bKXauxFWs7MIXUqFYLraUALZQRhg8KuDR2MKVtCqWU4rR6cbi2dOX7gin3s0sGpwk8hiX1TWliwesCn_0Hr8MSfYnWcy4op5ypguoDGmHC3nkbcgQzoscIU_BoXTnesKZplVC0Kf7sFl_GgLMztxY8OaZYdjMO_T66GeJN_-eLC3h-BJAMTDaCNy79dSWmLGF_JX16cBZCD2Ms5stnTpmgVDear4X4CczVvvk</recordid><startdate>200804</startdate><enddate>200804</enddate><creator>Brunzell, John D</creator><creator>Davidson, Michael</creator><creator>Furberg, Curt D</creator><creator>Goldberg, Ronald B</creator><creator>Howard, Barbara V</creator><creator>Stein, James H</creator><creator>Witztum, Joseph L</creator><general>American Diabetes Association</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7RV</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0K</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>200804</creationdate><title>Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation</title><author>Brunzell, John D ; Davidson, Michael ; Furberg, Curt D ; Goldberg, Ronald B ; Howard, Barbara V ; Stein, James H ; Witztum, Joseph L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-f282t-8ca26ca63e19ef44b98e936fd15e0c59838843a835c3c2d5a24cfdc9355e4443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Aqueous solutions</topic><topic>Biological and medical sciences</topic><topic>Blood lipoproteins</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>Cardiovascular Diseases - blood</topic><topic>Cardiovascular Diseases - epidemiology</topic><topic>Cardiovascular Diseases - prevention & control</topic><topic>Care and treatment</topic><topic>Cholesterol</topic><topic>Cholesterol, LDL - blood</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Diabetic Angiopathies - blood</topic><topic>Diabetic Angiopathies - epidemiology</topic><topic>Diabetic Angiopathies - prevention & control</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Heart failure</topic><topic>Humans</topic><topic>Kidney diseases</topic><topic>Lipoproteins</topic><topic>Lipoproteins - blood</topic><topic>Lipoproteins - metabolism</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Miscellaneous</topic><topic>Mortality</topic><topic>Other metabolic disorders</topic><topic>Physiological aspects</topic><topic>Plasma</topic><topic>Proteolipids</topic><topic>Public health</topic><topic>Public health. Hygiene</topic><topic>Public health. Hygiene-occupational medicine</topic><topic>Risk Factors</topic><topic>Societies, Medical</topic><topic>Type 2 diabetes</topic><topic>United States</topic><topic>Voluntary Health Agencies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brunzell, John D</creatorcontrib><creatorcontrib>Davidson, Michael</creatorcontrib><creatorcontrib>Furberg, Curt D</creatorcontrib><creatorcontrib>Goldberg, Ronald B</creatorcontrib><creatorcontrib>Howard, Barbara V</creatorcontrib><creatorcontrib>Stein, James H</creatorcontrib><creatorcontrib>Witztum, Joseph L</creatorcontrib><creatorcontrib>American College of Cardiology Foundation</creatorcontrib><creatorcontrib>American Diabetes Association</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Agricultural Science Database</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brunzell, John D</au><au>Davidson, Michael</au><au>Furberg, Curt D</au><au>Goldberg, Ronald B</au><au>Howard, Barbara V</au><au>Stein, James H</au><au>Witztum, Joseph L</au><aucorp>American College of Cardiology Foundation</aucorp><aucorp>American Diabetes Association</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation</atitle><jtitle>Diabetes care</jtitle><addtitle>Diabetes Care</addtitle><date>2008-04</date><risdate>2008</risdate><volume>31</volume><issue>4</issue><spage>811</spage><epage>822</epage><pages>811-822</pages><issn>0149-5992</issn><eissn>1935-5548</eissn><coden>DICAD2</coden><abstract>Central role of LDL in atherogenesis Among the many contributing factors, elevated cholesterol levels play a dominant role in both the initiation and progression of atherosclerosis, as well as in the clinical consequences such as myocardial infarction, stroke, peripheral vascular disease, and heart failure. In terms of dyslipoproteinemia, we recommend the following: * Statin therapy for the majority of dyslipoproteinemic adult patients with CMR * For patients with CMR on statin therapy, guiding therapy with measurements of apoB and treatment to apoB goals in addition to LDL cholesterol and non-HDL cholesterol assessments * Treatment goals, summarized in Table 1, that address the high lifetime risk of patients with dyslipoproteinemia and CMR. * Clinical trials to determine whether the pharmacologic therapy required to achieve very low levels of atherogenic lipoproteins is safe and cost-effective * A concerted, multifaceted, public health effort, focused on lifestyle modification, to reduce mean population levels of atherogenic lipoproteins to values well below current ones.</abstract><cop>Alexandria, VA</cop><pub>American Diabetes Association</pub><pmid>18375431</pmid><doi>10.2337/dc08-9018</doi><tpages>12</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0149-5992 |
ispartof | Diabetes care, 2008-04, Vol.31 (4), p.811-822 |
issn | 0149-5992 1935-5548 |
language | eng |
recordid | cdi_proquest_miscellaneous_70449356 |
source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
subjects | Aqueous solutions Biological and medical sciences Blood lipoproteins Cardiovascular disease Cardiovascular diseases Cardiovascular Diseases - blood Cardiovascular Diseases - epidemiology Cardiovascular Diseases - prevention & control Care and treatment Cholesterol Cholesterol, LDL - blood Diabetes Diabetes Mellitus, Type 2 - complications Diabetes. Impaired glucose tolerance Diabetic Angiopathies - blood Diabetic Angiopathies - epidemiology Diabetic Angiopathies - prevention & control Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Heart failure Humans Kidney diseases Lipoproteins Lipoproteins - blood Lipoproteins - metabolism Medical sciences Metabolic diseases Miscellaneous Mortality Other metabolic disorders Physiological aspects Plasma Proteolipids Public health Public health. Hygiene Public health. Hygiene-occupational medicine Risk Factors Societies, Medical Type 2 diabetes United States Voluntary Health Agencies |
title | Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T16%3A15%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lipoprotein%20Management%20in%20Patients%20With%20Cardiometabolic%20Risk:%20Consensus%20statement%20from%20the%20American%20Diabetes%20Association%20and%20the%20American%20College%20of%20Cardiology%20Foundation&rft.jtitle=Diabetes%20care&rft.au=Brunzell,%20John%20D&rft.aucorp=American%20College%20of%20Cardiology%20Foundation&rft.date=2008-04&rft.volume=31&rft.issue=4&rft.spage=811&rft.epage=822&rft.pages=811-822&rft.issn=0149-5992&rft.eissn=1935-5548&rft.coden=DICAD2&rft_id=info:doi/10.2337/dc08-9018&rft_dat=%3Cgale_proqu%3EA177953507%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223020215&rft_id=info:pmid/18375431&rft_galeid=A177953507&rfr_iscdi=true |